Therapeutic potential of melatonin and its analogs in Parkinson's disease: Focus on sleep and neuroprotection

Therapeutic Advances in Neurological Disorders

Volumn 4, Issue 5, 2011, Pages 297-317

  Srinivasan, Venkatramanujam ^a   Cardinali, Daniel P ^b   Srinivasan, Uddanapalli S ^c   Kaur, Charanjit ^d   Brown, Gregory M ^e   Spence, D Warren ^f   Hardeland, Rudiger ^g   Pandi Perumal, Seithikurippu R ^h  

^a Sri Sathya Sai Medical Educational and Research Foundation   (India)

^b PONTIFICIA UNIVERSIDAD CATÓLICA ARGENTINA   (Argentina)

^c Madras Institute of Orthopaedics and Traumatology Hospitals   (India)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^f University of Goettingen ^*  (Canada)

^g UNIVERSITY OF GÖTTINGEN   (Germany)

^h Somnogen Inc   (Canada)

Author keywords

agomelatine; insomnia; light therapy; melatonin; oxidative stress; Parkinson's disease; ramelteon; REM sleep behavior disorder; tasimelteon

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ACETYLCHOLINE; AGOMELATINE; ALBUMIN; ANTIPARKINSON AGENT; BENZODIAZEPINE DERIVATIVE; CALMODULIN; CATALASE; CLONAZEPAM; DOPAMINE; INDUCIBLE NITRIC OXIDE SYNTHASE; IRON; LEVODOPA; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; NEUROTOXIC ESTERASE; OREXIN; OXIDOPAMINE; PLACEBO; RAMELTEON; REACTIVE OXYGEN METABOLITE; ROTENONE; SEROTONIN UPTAKE INHIBITOR; SUPEROXIDE DISMUTASE; TASIMELTEON;

ALLODYNIA; AMYGDALOID NUCLEUS; ANALGESIC ACTIVITY; ANTINOCICEPTION; ANTIOXIDANT ACTIVITY; BREAST CANCER; CANCER INCIDENCE; CANCER INHIBITION; CANCER RISK; CANCER THERAPY; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CIRCADIAN RHYTHM; CLINICAL EVALUATION; DAYTIME SOMNOLENCE; DEPRESSION; DIGESTIVE SYSTEM CANCER; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSTHYMIA; EPWORTH SLEEPINESS SCALE; FOLLOW UP; GENE EXPRESSION; HALLUCINATION; HORMONE ACTION; HORMONE BINDING; HORMONE DETERMINATION; HUMAN; IMMUNE RESPONSE; INCIDENCE; INFLAMMATION; INSOMNIA; IRON DEFICIENCY; LEWY BODY; LIGHT EXPOSURE; LIPID PEROXIDATION; MELANOMA; MICROGLIA; MOLECULAR CLOCK; MOTOR DYSFUNCTION; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; NIGHTMARE; NIGRONEOSTRIATAL SYSTEM; NITROSATIVE STRESS; NOCTURNAL HALLUCINATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY; PITTSBURGH SLEEP QUALITY INDEX; POLYSOMNOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REM ASSOCIATED SLEEP BEHAVIOR DISORDER; REM SLEEP; REM SLEEP DEPRIVATION; REPRODUCTION; RESPIRATORY CHAIN; RESTLESS LEGS SYNDROME; REVIEW; SLEEP APNEA SYNDROME; SLEEP DISORDER; SLEEP WAKING CYCLE; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA PARS COMPACTA; SUPRACHIASMATIC NUCLEUS; TREATMENT DURATION;

EID: 80053324434     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285611406166     Document Type: Review

References (199)

1. Acuña-Castroviejo D. Coto-Montes A. Gaia M.M. Ortiz G.G. Reiter R.J. (1997) Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Sci 60: L23–L29.
2. Acuña Castroviejo D. Lopez L.C. Escames G. Lopez A. Garcia J.A. Reiter R.J. (2011) Melatonin-mitochondria Interplay in health and disease. Curr Top Med Chem 11: 221–240.
3. Adi N. Mash D.C. Ali Y. Singer C. Shehadeh L. Papapetropoulos S. (2010) Melatonin MT 1 and MT 2 receptor expression in Parkinson's disease. Med Sci Monit 16: BR61–BR67.
4. Adler C.H. (2005) Nonmotor complications in Parkinson's disease. Mov Disord 20(Suppl. 11): S23–S29.
5. Adler C.H. Thorpy M.J. (2005) Sleep issues in Parkinson's disease. Neurology 64: S12–S20.
6. Al Ghoul W.M. Herman M.D. Dubocovich M.L. (1998) Melatonin receptor subtype expression in human cerebellum. Neuroreport 9: 4063–4068.
7. Anderson K.N. Shneerson J.M. (2009) Drug treatment of REM sleep behavior disorder: the use of drug therapies other than clonazepam. J Clin Sleep Med 5: 235–239.
8. Antolin I. Mayo J.C. Sainz R.M. del Brio M.L. Herrera F. Martin V. et al (2002) Protective effect of melatonin in a chronic experimental model of Parkinson's disease. Brain Res 943: 163–173.
9. Arendt J. Skene D.J. (2005) Melatonin as a chronobiotic. Sleep Med Rev 9: 25–39.
10. Armstrong S.M. (1989) Melatonin and circadian control in mammals. Experientia 45: 932–938.
11. Arnulf I. Konofal E. Merino-Andreu M. Houeto J.L. Mesnage V. Welter M.L. et al (2002) Parkinson's disease and sleepiness: an integral part of PD. Neurology 58: 1019–1024.
12. Aurora R.N. Zak R.S. Maganti R.K. Auerbach S.H. Casey K.R. Chowdhuri S. et al (2010) Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med 6: 85–95.
13. Beach T.G. Adler C.H. Lue L. Sue L.I. Bachalakuri J. Henry-Watson J. et al (2009) Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 117: 613–634.
14. Beck-Friis J. Kjellman B.F. Aperia B. Unden F. von Rosen D. Ljunggren J.G. et al (1985) Serum melatonin in relation to clinical variables in patients with major depressive disorder and a hypothesis of a low melatonin syndrome. Acta Psychiatr Scand 71: 319–330.
15. Ben V. Bruguerolle B. (2000) Effects of bilateral striatal 6-OHDA lesions on circadian rhythms in the rat: a radiotelemetric study. Life Sci 67: 1549–1558.
16. Benitez-King G. (2006) Melatonin as a cytoskeletal modulator: implications for cell physiology and disease. J Pineal Res 40: 1–9.
17. Benitez-King G. Anton-Tay F. (1993) Calmodulin mediates melatonin cytoskeletal effects. Experientia 49: 635–641.
18. Berson D.M. Dunn F.A. Takao M. (2002) Phototransduction by retinal ganglion cells that set the circadian clock. Science 295: 1070–1073.
19. Blask D.E. Dauchy R.T. Sauer L.A. (2005) Putting cancer to sleep at night: the neuroendocrine / circadian melatonin signal. Endocrine 27: 179–188.
20. Boeve B.F. Dickson D.W. Olson E.J. Shepard J.W. Silber M.H. Ferman T.J. et al (2007 a) Insights into REM sleep behavior disorder pathophysiology in brainstem-predominant Lewy body disease. Sleep Med 8: 60–64.
21. Boeve B.F. Silber M.H. Ferman T.J. (2003) Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med 4: 281–284.
22. Boeve B.F. Silber M.H. Saper C.B. Ferman T.J. Dickson D.W. Parisi J.E. et al (2007 b) Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain 130: 2770–2788.
23. Boileau I. Warsh J.J. Guttman M. Saint-Cyr J.A. McCluskey T. Rusjan P. et al (2008) Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with [11C]DASB. Mov Disord 23: 1776–1780.
24. Borah A. Mohanakumar K.P. (2009) Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents. J Pineal Res 47: 293–300.
25. Borbely A.A. (1982) A two process model of sleep regulation. Hum Neurobiol 1: 195–204.
26. Bordet R. Devos D. Brique S. Touitou Y. Guieu J.D. Libersa C. et al (2003) Study of circadian melatonin secretion pattern at different stages of Parkinson's disease. Clin Neuropharmacol 26: 65–72.
27. Borland M.K. Mohanakumar K.P. Rubinstein J.D. Keeney P.M. Xie J. Capaldi R. et al (2009) Relationships among molecular genetic and respiratory properties of Parkinson's disease cybrid cells show similarities to Parkinson's brain tissues. Biochim Biophys Acta 1792: 68–74.
28. Braak H. Del Tredici K. Rub U. de Vos R.A. Jansen Steur E.N. Braak E. (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24: 197–211.
29. Braak H. Sastre M. Bohl J.R. de Vos R.A. Del Tredici K. (2007) Parkinson's disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol 113: 421–429.
30. Brainard G.C. Hanifin J.P. Rollag M.D. Greeson J. Byrne B. Glickman G. et al (2001) Human melatonin regulation is not mediated by the three cone photopic visual system. J Clin Endocrinol Metab 86: 433–436.
31. Brown G.C. Bal-Price A. (2003) Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Mol Neurobiol 27: 325–355.
32. Brown G.C. Borutaite V. (2004) Inhibition of mitochondrial respiratory complex I by nitric oxide, peroxynitrite and S-nitrosothiols. Biochim Biophys Acta 1658: 44–49.
33. Bruguerolle B. Simon N. (2002) Biologic rhythms and Parkinson's disease: a chronopharmacologic approach to considering fluctuations in function. Clin Neuropharmacol 25: 194–201.
34. Cai Y. Ding H. Li N. Chai Y. Zhang Y. Chan P. (2010 a) Oscillation development for neurotransmitter-related genes in the mouse striatum. Neuroreport 21: 79–83.
35. Cai Y. Liu S. Sothern R.B. Xu S. Chan P. (2010 b) Expression of clock genes Per 1 and Bmal 1 in total leukocytes in health and Parkinson's disease. Eur J Neurol 17: 550–554.
36. Cardinali D.P. Furio A.M. Reyes M.P. Brusco L.I. (2006) The use of chronobiotics in the resynchronization of the sleep-wake cycle. Cancer Causes Control 17: 601–609.
37. Cardinali D.P. Lynch H.J. Wurtman R.J. (1972) Binding of melatonin to human and rat plasma proteins. Endocrinology 91: 1213–1218.
38. Carretero M. Escames G. Lopez L.C. Venegas C. Dayoub J.C. Garcia L. et al (2009) Long-term melatonin administration protects brain mitochondria from aging. J Pineal Res in press.
39. Catala M.D. Canete-Nicolas C. Iradi A. Tarazona P.J. Tormos J.M. Pascual-Leone A. (1997) Melatonin levels in Parkinson's disease: drug therapy versus electrical stimulation of the internal globus pallidus. Exp Gerontol 32: 553–558.
40. Ceravolo R. Rossi C. Kiferle L. Bonuccelli U. (2010) Nonmotor symptoms in Parkinson's disease: the dark side of the moon. Future Neurology 5: 851–871.
41. Cermakian N. Monaco L. Pando M.P. Dierich A. Sassone-Corsi P. (2001) Altered behavioral rhythms and clock gene expression in mice with a targeted mutation in the Period 1 gene. EMBO J 20: 3967–3974.
42. Chaudhuri K.R. Healy D.G. Schapira A.H. (2006) Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 5: 235–245.
43. Chaudhuri K.R. Pal S. DiMarco A. Whately-Smith C. Bridgman K. Mathew R. et al (2002) The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. J Neurol Neurosurg Psychiatry 73: 629–635.
44. Comella C.L. (2006) Sleep disturbances and excessive daytime sleepiness in Parkinson disease: an overview. J Neural Transm Suppl 349–355.
45. Comella C.L. (2007) Sleep disorders in Parkinson's disease: an overview. Mov Disord 22(Suppl. 17): S367–S373.
46. Compta Y. Santamaria J. Ratti L. Tolosa E. Iranzo A. Munoz E. et al (2009) Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementia. Brain 132: 3308–3317.
47. Dabbeni-Sala F. Di Santo S. Franceschini D. Skaper S.D. Giusti P. (2001) Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity. FASEB J 15: 164–170.
48. Dawson D. Armstrong S.M. (1996) Chronobiotics–drugs that shift rhythms. Pharmacol Ther 69: 15–36.
49. Deacon S. Arendt J. (1995) Melatonin-induced temperature suppression and its acute phase-shifting effects correlate in a dose-dependent manner in humans. Brain Res 688: 77–85.
50. Dhawan V. Dhoat S. Williams A.J. DiMarco A. Pal S. Forbes A. et al (2006 a) The range and nature of sleep dysfunction in untreated Parkinson's disease (PD). A comparative controlled clinical study using the Parkinson's disease sleep scale and selective polysomnography. J Neurol Sci 248: 158–162.
51. Dhawan V. Healy D.G. Pal S. Chaudhuri K.R. (2006 b) Sleep-related problems of Parkinson's disease. Age Ageing 35: 220–228.
52. Dibner C. Schibler U. Albrecht U. (2010) The mammalian circadian timing system: organization and coordination of central and peripheral clocks. Annu Rev Physiol 72: 517–549.
53. Dijk D.J. Shanahan T.L. Duffy J.F. Ronda J.M. Czeisler C.A. (1997) Variation of electroencephalographic activity during non-rapid eye movement and rapid eye movement sleep with phase of circadian melatonin rhythm in humans. J Physiol 505: 851–858.
54. Dobkin R.D. Menza M. Bienfait K.L. Gara M. Marin H. Mark M.H. et al (2010) Depression in Parkinson's disease: symptom improvement and residual symptoms after acute pharmacologic management. Am J Geriatr Psychiatry in press.
55. Dowling G.A. Mastick J. Colling E. Carter J.H. Singer C.M. Aminoff M.J. (2005) Melatonin for sleep disturbances in Parkinson's disease. Sleep Med 6: 459–466.
56. Dubocovich M.L. Delagrange P. Krause D.N. Sugden D. Cardinali D.P. Olcese J. (2010) International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol Rev 62: 343–380.
57. Edgar D.M. Dement W.C. Fuller C.A. (1993) Effect of SCN lesions on sleep in squirrel monkeys: evidence for opponent processes in sleep–wake regulation. J Neurosci 13: 1065–1079.
58. Elbaz A. Moisan F. (2008) Update in the epidemiology of Parkinson's disease. Curr Opin Neurol 21: 454–460.
59. Erman M. Seiden D. Zammit G. Sainati S. Zhang J. (2006) An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Med 7: 17–24.
60. Erro M.E. Moreno M.P. Zandio B. (2010) [Pathophysiological bases of the non-motor symptoms in Parkinson's disease]. Rev Neurol 50(Suppl. 2): S7–S13.
61. Eser D. Baghai T.C. Moller H.J. (2010) Agomelatine: The evidence for its place in the treatment of depression. Core Evid 4: 171–179.
62. Esteves A.R. Lu J. Rodova M. Onyango I. Lezi E. Dubinsky R. et al (2010) Mitochondrial respiration and respiration-associated proteins in cell lines created through Parkinson's subject mitochondrial transfer. J Neurochem 113: 674–682.
63. Fahn S. Cohen G. (1992) The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 32: 804–812.
64. Fertl E. Auff E. Doppelbauer A. Waldhauser F. (1991) Circadian secretion pattern of melatonin in Parkinson's disease. J Neural Transm Park Dis Dement Sect 3: 41–47.
65. Fertl E. Auff E. Doppelbauer A. Waldhauser F. (1993) Circadian secretion pattern of melatonin in de novo parkinsonian patients: evidence for phase-shifting properties of l-dopa. J Neural Transm Park Dis Dement Sect 5: 227–234.
66. Friedman J.H. Chou K.L. (2004) Sleep and fatigue in Parkinson's disease. Parkinsonism Relat Disord 10(Suppl. 1): S27–S35.
67. Fukuya H. Emoto N. Nonaka H. Yagita K. Okamura H. Yokoyama M. (2007) Circadian expression of clock genes in human peripheral leukocytes. Biochem Biophys Res Commun 354: 924–928.
68. Garcia-Borreguero D. Larrosa O. Bravo M. (2003) Parkinson's disease and sleep. Sleep Med Rev 7: 115–129.
69. Gibson G.E. Starkov A. Blass J.P. Ratan R.R. Beal M.F. (2010) Cause and consequence: mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative diseases. Biochim Biophys Acta 1802: 122–134.
70. Gilad E. Zisapel N. (1995) High-affinity binding of melatonin to hemoglobin. Biochem Mol Med 56: 115–120.
71. Grandas F. Iranzo A. (2004) Nocturnal problems occurring in Parkinson's disease. Neurology 63: S8–S11.
72. Guerrero J.M. Reiter R.J. (2002) Melatonin-immune system relationships. Curr Top Med Chem 2: 167–179.
73. Hale A. Corral R.M. Mencacci C. Ruiz J.S. Severo C.A. Gentil V. (2010) Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study. Int Clin Psychopharmacol 25: 305–314.
74. Happe S. Klosch G. Lorenzo J. Kunz D. Penzel T. Roschke J. et al (2005) Perception of sleep: subjective versus objective sleep parameters in patients with Parkinson's disease in comparison with healthy elderly controls. Sleep perception in Parkinson's disease and controls. J Neurol 252: 936–943.
75. Happe S. Ludemann P. Berger K. (2002) The association between disease severity and sleep-related problems in patients with Parkinson's disease. Neuropsychobiology 46: 90–96.
76. Hardeland R. Cardinali D.P. Srinivasan V. Spence D.W. Brown G.M. Pandi-Perumal S.R. (2011) Melatonin–a pleiotropic, orchestrating regulator molecule. Progr Neurobiol 93: 350–384.
77. Hardeland R. Tan D.X. Reiter R.J. (2009) Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines. J Pineal Res 47: 109–116.
78. Hilker R. Razai N. Ghaemi M. Weisenbach S. Rudolf J. Szelies B. et al (2003) [18F]fluorodopa uptake in the upper brainstem measured with positron emission tomography correlates with decreased REM sleep duration in early Parkinson's disease. Clin Neurol Neurosurg 105: 262–269.
79. Hirata F. Hayaishi O. Tokuyama T. Seno S. (1974) In vitro and in vivo formation of two new metabolites of melatonin. J Biol Chem 249: 1311–1313.
80. Hobson D.E. Lang A.E. Martin W.R. Razmy A. Rivest J. Fleming J. (2002) Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA 287: 455–463.
81. Itoh N. Masuo Y. Yoshida Y. Cynshi O. Jishage K. Niki E. (2006) γ-Tocopherol attenuates MPTP-induced dopamine loss more efficiently than α-tocopherol in mouse brain. Neurosci Lett 403: 136–140.
82. Jahan I. Hauser R.A. Sullivan K.L. Miller A. Zesiewicz T.A. (2009) Sleep disorders in Parkinson's disease. Neuropsychiatr Dis Treat 5: 535–540.
83. Kasper S. Hajak G. Wulff K. Hoogendijk W.J. Montejo A.L. Smeraldi E. et al (2010) Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry 71: 109–120.
84. Kato K. Hirai K. Nishiyama K. Uchikawa O. Fukatsu K. Ohkawa S. et al (2005) Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 48: 301–310.
85. Kaynak D. Kiziltan G. Kaynak H. Benbir G. Uysal O. (2005) Sleep and sleepiness in patients with Parkinson's disease before and after dopaminergic treatment. Eur J Neurol 12: 199–207.
86. Keeney P.M. Dunham L.D. Quigley C.K. Morton S.L. Bergquist K.E. Bennett J.P. Jr (2009 a) Cybrid models of Parkinson's disease show variable mitochondrial biogenesis and genotype-respiration relationships. Exp Neurol 220: 374–382.
87. Keeney P.M. Quigley C.K. Dunham L.D. Papageorge C.M. Iyer S. Thomas R.R. et al (2009 b) Mitochondrial gene therapy augments mitochondrial physiology in a Parkinson's disease cell model. Hum Gene Ther 20: 897–907.
88. Klein D.C. Weller J.L. Moore R.Y. (1971) Melatonin metabolism: neural regulation of pineal serotonin: acetyl coenzyme A N-acetyltransferase activity. Proc Natl Acad Sci U S A 68: 3107–3110.
89. Kondratov R.V. Kondratova A.A. Gorbacheva V.Y. Vykhovanets O.V. Antoch M.P. (2006) Early aging and age-related pathologies in mice deficient in BMAL1, the core component of the circadian clock. Genes Dev 20: 1868–1873.
90. Kortekaas R. Leenders K.L. van Oostrom J.C. Vaalburg W. Bart J. Willemsen A.T. et al (2005) Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 57: 176–179.
91. Kunz D. Bes F. (1997) Melatonin effects in a patient with severe REM sleep behavior disorder: case report and theoretical considerations. Neuropsychobiology 36: 211–214.
92. Kunz D. Bes F. (1999) Melatonin as a therapy in REM sleep behavior disorder patients: an open-labeled pilot study on the possible influence of melatonin on REM-sleep regulation. Mov Disord 14: 507–511.
93. Lam R.W. (2006) Sleep disturbances and depression: a challenge for antidepressants. Int Clin Psychopharmacol 21(Suppl. 1): S25–S29.
94. Larsen J.P. (2003) Sleep disorders in Parkinson's disease. Adv Neurol 91: 329–334.
95. Lavie P. Wajsbort J. Youdim M.B. (1980) Deprenyl does not cause insomnia in parkinsonian patients. Commun Psychopharmacol 4: 303–307.
96. Lees A.J. Blackburn N.A. Campbell V.L. (1988) The nighttime problems of Parkinson's disease. Clin Neuropharmacol 11: 512–519.
97. Leston J. Harthe C. Brun J. Mottolese C. Mertens P. Sindou M. et al (2010) Melatonin is released in the third ventricle in humans. A study in movement disorders. Neurosci Lett 469: 294–297.
98. Lewy A.J. Sack R.A. Singer C.L. (1984) Assessment and treatment of chronobiologic disorders using plasma melatonin levels and bright light exposure: the clock-gate model and the phase response curve. Psychopharmacol Bull 20: 561–565.
99. Liu C. Weaver D.R. Jin X. Shearman L.P. Pieschl R.L. Gribkoff V.K. et al (1997) Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 19: 91–102.
100. Liu S. Cai Y. Sothern R.B. Guan Y. Chan P. (2007) Chronobiological analysis of circadian patterns in transcription of seven key clock genes in six peripheral tissues in mice. Chronobiol Int 24: 793–820.
101. Loo H. Hale A. D'haenen H. (2002) Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 17: 239–247.
102. Lustberg L. Reynolds C.F. (2000) Depression and insomnia: questions of cause and effect. Sleep Med Rev 4: 253–262.
103. Maguire-Zeiss K.A. Federoff H.J. (2010) Future directions for immune modulation in neurodegenerative disorders: focus on Parkinson's disease. J Neural Transm 117: 1019–1025.
104. Maharaj H. Sukhdev M.D. Scheepers M. Mokokong R. Daya S. (2005) l-DOPA administration enhances 6-hydroxydopamine generation. Brain Res 1063: 180–186.
105. Marion M.H. Qurashi M. Marshall G. Foster O. (2008) Is REM sleep behaviour disorder (RBD) a risk factor of dementia in idiopathic Parkinson's disease? J Neurol 255: 192–196.
106. Means M.K. Edinger J.D. Glenn D.M. Fins A.I. (2003) Accuracy of sleep perceptions among insomnia sufferers and normal sleepers. Sleep Med 4: 285–296.
107. Medeiros C.A. Carvalhedo de Bruin P.F. Lopes L.A. Magalhaes M.C. de Lourdes S.M. Sales de Bruin V. (2007) Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease: A randomized, double blind, placebo-controlled study. J Neurol 254: 459–464.
108. Medeiros C.A. Carvalhedo de Bruin P.F. Lopes L.A. Magalhaes M.C. de Lourdes S.M. Sales de Bruin V. (2008) Melatonin in Parkinson's disease. J Neurol 255: 758–759.
109. Mehta S.H. Morgan J.C. Sethi K.D. (2008) Sleep disorders associated with Parkinson's disease: role of dopamine, epidemiology, and clinical scales of assessment. CNS Spectr 13: 6–11.
110. Mena-Segovia J. Cintra L. Prospero-Garcia O. Giordano M. (2002) Changes in sleep-waking cycle after striatal excitotoxic lesions. Behav Brain Res 136: 475–481.
111. Moltzen E.K. Bang-Andersen B. (2006) Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century–a medicinal chemistry survey. Curr Top Med Chem 6: 1801–1823.
112. Monahan A.J. Warren M. Carvey P.M. (2008) Neuroinflammation and peripheral immune infiltration in Parkinson's disease: an autoimmune hypothesis. Cell Transplant 17: 363–372.
113. Monderer R. Thorpy M. (2009) Sleep disorders and daytime sleepiness in Parkinson's disease. Curr Neurol Neurosci Rep 9: 173–180.
114. Morgan W.W. Nelson J.F. (2001) Chronic administration of pharmacological levels of melatonin does not ameliorate the MPTP-induced degeneration of the nigrostriatal pathway. Brain Res 921: 115–121.
115. Naismith S.L. Rogers N.L. Mackenzie J. Hickie I.B. Lewis S.J. (2010) The relationship between actigraphically defined sleep disturbance and REM sleep behaviour disorder in Parkinson's Disease. Clin Neurol Neurosurg 112: 420–423.
116. Nomura T. Inoue Y. Miyake M. Yasui K. Nakashima K. (2006) Prevalence and clinical characteristics of restless legs syndrome in Japanese patients with Parkinson's disease. Mov Disord 21: 380–384.
117. Okatani Y. Wakatsuki A. Reiter R.J. Miyahara Y. (2003) Acutely administered melatonin restores hepatic mitochondrial physiology in old mice. Int J Biochem Cell Biol 35: 367–375.
118. Olanow C.W. (1992) An introduction to the free radical hypothesis in Parkinson's disease. Ann Neurol 32(Suppl): S2–S9.
119. Olson E.J. Boeve B.F. Silber M.H. (2000) Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain 123: 331–339.
120. Ondo W.G. Vuong K.D. Jankovic J. (2002) Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol 59: 421–424.
121. Pandi-Perumal S.R. Srinivasan V. Cardinali D.P. Monti M.J. (2006 a) Could agomelatine be the ideal antidepressant? Expert Rev Neurother 6: 1595–1608.
122. Pandi-Perumal S.R. Srinivasan V. Maestroni G.J.M. Cardinali D.P. Poeggeler B. Hardeland R. (2006 b) Melatonin: Nature's most versatile biological signal? FEBS J 273: 2813–2838.
123. Paulus W. Jellinger K. (1991) The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 50: 743–755.
124. Pérez Lloret S. Rossi M. Cardinali D.P. Merello M. (2010) Activity-rest rhythm abnormalities in Parkinson's disease patients are related to dopaminergic therapy. Int J Neurosci 120: 11–16.
125. Pérez Lloret S. Rossi M. Nouzeilles M.I. Trenkwalder C. Carreras L.O. Merello M. (2009) Parkinson's disease sleep scale, sleep logs, and actigraphy in the evaluation of sleep in parkinsonian patients. J Neurol 256: 1480–1484.
126. Pévet P. Bothorel B. Slotten H. Saboureau M. (2002) The chronobiotic properties of melatonin. Cell Tissue Res 309: 183–191.
127. Postuma R.B. Gagnon J.F. Montplaisir J. (2010) Clinical prediction of Parkinson's disease: planning for the age of neuroprotection. J Neurol Neurosurg Psychiatry 81: 1008–1013.
128. Rajaratnam S.M. Middleton B. Stone B.M. Arendt J. Dijk D.J. (2004) Melatonin advances the circadian timing of EEG sleep and directly facilitates sleep without altering its duration in extended sleep opportunities in humans. J Physiol 561: 339–351.
129. Rajaratnam S.M. Polymeropoulos M.H. Fisher D.M. Roth T. Scott C. Birznieks G. et al (2009) Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet 373: 482–491.
130. Ravina B. Elm J. Camicioli R. Como P.G. Marsh L. Jankovic J. et al (2009) The course of depressive symptoms in early Parkinson's disease. Mov Disord 24: 1306–1311.
131. Reijnders J.S. Ehrt U. Weber W.E. Aarsland D. Leentjens A.F. (2008) A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 23: 183–189.
132. Reiter R.J. (1980) The pineal and its hormones in the control of reproduction in mammals. Endocr Rev 1: 109–131.
133. Reiter R.J. Tan D.X. Fuentes-Broto L. (2010) Melatonin: a multitasking molecule. Prog Brain Res 181: 127–151.
134. Remy P. Doder M. Lees A. Turjanski N. Brooks D. (2005) Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128: 1314–1322.
135. Richardson G.S. Zammit G. Wang-Weigand S. Zhang J. (2009) Safety and subjective sleep effects of ramelteon administration in adults and older adults with chronic primary insomnia: a 1-year, open-label study. J Clin Psychiatry 70: 467–476.
136. Riemann D. Berger M. Voderholzer U. (2001) Sleep and depression–results from psychobiological studies: an overview. Biol Psychol 57: 67–103.
137. Rockenstein E. Crews L. Masliah E. (2007) Transgenic animal models of neurodegenerative diseases and their application to treatment development. Adv Drug Deliv Rev 59: 1093–1102.
138. Rod N.H. Hansen J. Schernhammer E. Ritz B. (2010) Major life events and risk of Parkinson's disease. Mov Disord 25: 1639–1645.
139. Rodriguez M.I. Escames G. Lopez L.C. Lopez A. Garcia J.A. Ortiz F. et al (2008) Improved mitochondrial function and increased life span after chronic melatonin treatment in senescent prone mice. Exp Gerontol 43: 749–756.
140. Rosenthal N.E. Sack D.A. Gillin J.C. Lewy A.J. Goodwin F.K. Davenport Y. et al (1984) Seasonal affective disorder. A description of the syndrome and preliminary findings with light therapy. Arch Gen Psychiatry 41: 72–80.
141. Roth T. Seiden D. Wang-Weigand S. Zhang J. (2007) A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin 23: 1005–1014.
142. Sack R.L. Lewy A.J. Blood M.L. Keith L.D. Nakagawa H. (1992) Circadian rhythm abnormalities in totally blind people: incidence and clinical significance. J Clin Endocrinol Metab 75: 127–134.
143. Sandyk R. (1997) The accelerated aging hypothesis of Parkinson's disease is not supported by the pattern of circadian melatonin secretion. Int J Neurosci 90: 271–275.
144. Saper C.B. Lu J. Chou T.C. Gooley J. (2005) The hypothalamic integrator for circadian rhythms. Trends Neurosci 28: 152–157.
145. Saravanan K.S. Sindhu K.M. Mohanakumar K.P. (2007) Melatonin protects against rotenone-induced oxidative stress in a hemiparkinsonian rat model. J Pineal Res 42: 247–253.
146. Savaskan E. Olivieri G. Meier F. Brydon L. Jockers R. Ravid R. et al (2002) Increased melatonin 1a-receptor immunoreactivity in the hippocampus of Alzheimer's disease patients. J Pineal Res 32: 59–62.
147. Savica R. Rocca W.A. Ahlskog J.E. (2010) When does Parkinson disease start? Arch Neurol 67: 798–801.
148. Scaravilli T. Gasparoli E. Rinaldi F. Polesello G. Bracco F. (2003) Health-related quality of life and sleep disorders in Parkinson's disease. Neurol Sci 24: 209–210.
149. Scheer F.A. Wright K.P. Jr Kronauer R.E. Czeisler C.A. (2007) Plasticity of the intrinsic period of the human circadian timing system. PloS ONE 2: e721–e721.
150. Schenck C.H. Bundlie S.R. Mahowald M.W. (1996) Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 46: 388–393.
151. Schernhammer E. Chen H. Ritz B. (2006) Circulating melatonin levels: possible link between Parkinson's disease and cancer risk? Cancer Causes Control 17: 577–582.
152. Schober A. (2004) Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res 318: 215–224.
153. Shiba M. Bower J.H. Maraganore D.M. McDonnell S.K. Peterson B.J. Ahlskog J.E. et al (2000) Anxiety disorders and depressive disorders preceding Parkinson's disease: a case–control study. Mov Disord 15: 669–677.
154. Silva S.O. Ximenes V.F. Livramento J.A. Catalani L.H. Campa A. (2005) High concentrations of the melatonin metabolite, N1-acetyl-N2-formyl-5-methoxykynuramine, in cerebrospinal fluid of patients with meningitis: a possible immunomodulatory mechanism. J Pineal Res 39: 302–306.
155. Simuni T. (2004) Somnolence and other sleep disorders in Parkinson's disease: the challenge for the practicing neurologist. Neurol Clin 22: S107–S126.
156. Singhal N.K. Srivastava G. Patel D.K. Jain S.K. Singh M.P. (2011) Melatonin or silymarin reduces maneb- and paraquat-induced Parkinson's disease phenotype in the mouse. J Pineal Res 50: 97–109.
157. Srinivasan V. Maestroni G. Cardinali D. Esquifino A. Perumal S.P. Miller S. (2005) Melatonin, immune function and aging. Immun Ageing 2: 17–18.
158. Srinivasan V. Pandi-Perumal S.R. Spence D.W. Moscovitch A. Trakht I. Brown G.M. et al (2010) Potential use of melatonergic drugs in analgesia: mechanisms of action. Brain Res Bull 81: 362–371.
159. Srinivasan V. Pandi-Perumal S.R. Trakht I. Spence D.W. Hardeland R. Poeggeler B. et al (2009 a) Pathophysiology of depression: role of sleep and the melatonergic system. Psychiatry Res 165: 201–214.
160. Srinivasan V. Spence D.W. Pandi-Perumal S.R. Trakht I. Cardinali D.P. (2008) Therapeutic actions of melatonin in cancer: possible mechanisms. Integrative Cancer Therapies 7: 189–203.
161. Srinivasan V. Spence W.D. Pandi-Perumal S.R. Zakharia R. Bhatnagar K.P. Brzezinski A. (2009 b) Melatonin and human reproduction: shedding light on the darkness hormone. Gynecol Endocrinol 25: 779–785.
162. Stevens R.G. Hansen J. Costa G. Haus E. Kauppinen T. Aronson K.J. et al (2011) Considerations of circadian impact for defining ‘shift work’ in cancer studies: IARC Working Group Report. Occup Environ Med 68: 154–162.
163. Suzuki K. Okuma Y. Hattori N. Kamei S. Yoshii F. Utsumi H. et al (2007) Characteristics of sleep disturbances in Japanese patients with Parkinson's disease. A study using Parkinson's disease sleep scale. Mov Disord 22: 1245–1251.
164. Takeuchi N. Uchimura N. Hashizume Y. Mukai M. Etoh Y. Yamamoto K. et al (2001) Melatonin therapy for REM sleep behavior disorder. Psychiatry Clin Neurosci 55: 267–269.
165. Tan D.X. Manchester L.C. Burkhardt S. Sainz R.M. Mayo J.C. Kohen R. et al (2001) N1-acetyl-N2-formyl-5-methoxykynuramine, a biogenic amine and melatonin metabolite, functions as a potent antioxidant. FASEB J 15: 2294–2296.
166. Tan D.X. Manchester L.C. Reiter R.J. Plummer B.F. Hardies L.J. Weintraub S.T. et al (1998) A novel melatonin metabolite, cyclic 3-hydroxymelatonin: a biomarker of in vivo hydroxyl radical generation. Biochem Biophys Res Commun 253: 614–620.
167. Tandberg E. Larsen J.P. Karlsen K. (1999) Excessive daytime sleepiness and sleep benefit in Parkinson's disease: a community-based study. Mov Disord 14: 922–927.
168. Tansey M.G. Goldberg M.S. (2010) Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37: 510–518.
169. Tansey M.G. McCoy M.K. Frank-Cannon T.C. (2007) Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 208: 1–25.
170. Tapias V. Escames G. Lopez L.C. Lopez A. Camacho E. Carrion M.D. et al (2009) Melatonin and its brain metabolite N 1-acetyl-5-methoxykynuramine prevent mitochondrial nitric oxide synthase induction in parkinsonian mice. J Neurosci Res 87: 3002–3010.
171. Terzioglu M. Galter D. (2008) Parkinson's disease: genetic versus toxin-induced rodent models. FEBS J 275: 1384–1391.
172. Thannickal T.C. Lai Y.Y. Siegel J.M. (2007) Hypocretin (orexin) cell loss in Parkinson's disease. Brain 130: 1586–1595.
173. Thannickal T.C. Lai Y.Y. Siegel J.M. (2008) Hypocretin (orexin) and melanin concentrating hormone loss and the symptoms of Parkinson's disease. Brain 131: e87–e87.
174. The Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N Engl J Med 328: 176–183.
175. Thomas B. Mohanakumar K.P. (2004) Melatonin protects against oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the mouse nigrostriatum. J Pineal Res 36: 25–32.
176. Trenkwalder C. (1998) Sleep dysfunction in Parkinson's disease. Clin Neurosci 5: 107–114.
177. Tricoire H. Moller M. Chemineau P. Malpaux B. (2003) Origin of cerebrospinal fluid melatonin and possible function in the integration of photoperiod. Reprod Suppl 61: 311–321.
178. Ubhi K. Rockenstein E. Mante M. Inglis C. Adame A. Patrick C. et al (2010) Alpha-synuclein deficient mice are resistant to toxin-induced multiple system atrophy. Neuroreport 21: 457–462.
179. Uz T. Arslan A.D. Kurtuncu M. Imbesi M. Akhisaroglu M. Dwivedi Y. et al (2005) The regional and cellular expression profile of the melatonin receptor MT 1 in the central dopaminergic system. Brain Res Mol Brain Res 136: 45–53.
180. van der Schyf C.J. Castagnoli K. Palmer S. Hazelwood L. Castagnoli N. Jr (2000) Melatonin fails to protect against long-term MPTP-induced dopamine depletion in mouse striatum. Neurotox Res 1: 261–269.
181. van Hilten B. Hoff J.I. Middelkoop H.A. van der Velde E.A. Kerkhof G.A. Wauquier A. et al (1994) Sleep disruption in Parkinson's disease. Assessment by continuous activity monitoring. Arch Neurol 51: 922–928.
182. Vendette M. Gagnon J.F. Decary A. Massicotte-Marquez J. Postuma R.B. Doyon J. et al (2007) REM sleep behavior disorder predicts cognitive impairment in Parkinson disease without dementia. Neurology 69: 1843–1849.
183. Wehr T.A. Aeschbach D. Duncan W.C. Jr (2001) Evidence for a biological dawn and dusk in the human circadian timing system. J Physiol 535: 937–951.
184. Weintraub D. Mavandadi S. Mamikonyan E. Siderowf A.D. Duda J.E. Hurtig H.I. et al (2010) Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology 75: 448–455.
185. Weintraub D. Moberg P.J. Duda J.E. Katz I.R. Stern M.B. (2004) Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease. J Am Geriatr Soc 52: 784–788.
186. Weisskopf M.G. Chen H. Schwarzschild M.A. Kawachi I. Ascherio A. (2003) Prospective study of phobic anxiety and risk of Parkinson's disease. Mov Disord 18: 646–651.
187. Wiesenberg I. Missbach M. Carlberg C. (1998) The potential role of the transcription factor RZR / ROR as a mediator of nuclear melatonin signaling. Restor Neurol Neurosci 12: 143–150.
188. Willis G.L. (2008) Parkinson's disease as a neuroendocrine disorder of circadian function: dopamine-melatonin imbalance and the visual system in the genesis and progression of the degenerative process. Rev Neurosci 19: 245–316.
189. Willis G.L. Armstrong S.M. (1999) A therapeutic role for melatonin antagonism in experimental models of Parkinson's disease. Physiol Behav 66: 785–795.
190. Willis G.L. Turner E.J. (2007) Primary and secondary features of Parkinson's disease improve with strategic exposure to bright light: a case series study. Chronobiol Int 24: 521–537.
191. Wu Y. Le W. Jankovic J. (2011) Preclinical biomarkers of Parkinson disease. Arch Neurol 68: 22–30.
192. Wurtman R.J. Zhdanova I. (1995) Improvement of sleep quality by melatonin. Lancet 346: 1491–1492.
193. Young A. Home M. Churchward T. Freezer N. Holmes P. Ho M. (2002) Comparison of sleep disturbance in mild versus severe Parkinson's disease. Sleep 25: 573–577.
194. Zammit G. Erman M. Wang-Weigand S. Sainati S. Zhang J. Roth T. (2007) Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med 3: 495–504.
195. Zhang J. Perry G. Smith M.A. Robertson D. Olson S.J. Graham D.G. et al (1999) Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol 154: 1423–1429.
196. Zhang L. Dawson V.L. Dawson T.M. (2006) Role of nitric oxide in Parkinson's disease. Pharmacol Ther 109: 33–41.
197. Zhang Y. Dawson V.L. Dawson T.M. (2000) Oxidative stress and genetics in the pathogenesis of Parkinson's disease. Neurobiol Dis 7: 240–250.
198. Zlokovic B.V. (2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57: 178–201.
199. Zupancic M. Guilleminault C. (2006) Agomelatine: a preliminary review of a new antidepressant. CNS Drugs 20: 981–992.